Burden of hepatocellular carcinoma in Iran; Bayesian projection and trend analysis

Asian Pacific Journal of Cancer Prevention

Volumn 11, Issue 4, 2010, Pages 859-862

  Pourhoseingholi, Mohamad Amin ^a   Fazeli, Zeinab ^b   Zali, Mohammad Reza ^c   Alavian, Seyed Moayed ^a  

^a BAQIYATALLAH UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Hepatocellular carcinoma; Mortality; Years of life lost

Indexed keywords

EID: 78650693387     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Alavian SM (2006). Immunization: An important strategy to control hepatitis B. Hepat Mon, 6, 3-5.
2. Alavian SM, Adibi P, Zali MR (2005). Hepatitis C virus in Iran: epidemiology of an emerging infection. Arch Iranian Med, 8, 84-90.
3. Alavian SM, Ahmadzad Asl M, Lankarani KB, et al (2009). Hepatitis C infection in the general population of Iran: A systematic review. Hepat Mon, 9, 211-23.
4. Alavian SM, Fallahian F, Lankarani KB (2007). The changing epidemiology of viral hepatitis B in Iran. J Gastrointestin Liver Dis, 16, 403-6.
5. Alavian SM, Hajarizadeh B, Ahmadzad-Asl M, et al (2008). Hepatitis B virus infection in Iran: A systematic review. Hepat Mon, 8, 281-94.
6. Bosch FX, Ribes J, Diaz M, et al (2004). Primary liver cancer: worldwide incidence and trends. Gastroenterology, 127, 5-16.
7. Burnet NG, Jefferies SJ, Benson RJ, et al (2005). Years of life lost (YLL) from cancer is an important measure of population burden-and should be considered when allocating research funds. Br J Cancer, 92, 241-5.
8. Chen CJ, Yu MW, Liaw YF (1997). Epidemiological characteristics and risk factors of hepatocellular carcinoma. J Gastroenterol Hepatol, 12, 294-308.
9. Colombo M, Kuo G, Choo Q, et al (1989). Prevalence of antibodies to hepatitis C virus in Italian patients with Hepatocellular carcinoma. Lancet, 2, 1006-8.
10. Deuffic S, Poynard T, Buffa L, et al (1998). Trends in primary liver cancer. Lancet, 351, 214-5.
11. Dyer Z, Peltekian K, van Zanten SV (2005). Review article: the changing epidemiology of hepatocellular carcinoma in Canada. Aliment Pharmacol Ther, 22, 17-22.
12. El Serag HB, Mason AC (1999). Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med, 340, 745-50.
13. Fani A, Fani I, Eshrati B, et al (2007). Screening for hepatocellular carcinoma in chronic carriers of hepatitis B and C in markazi province, Iran. Hepat Mon, 7, 149-52.
14. Gardner JW, Sanborn JS (1990). Years of potential life lost (YPLL)-what does it measure? Epidemiology, 1, 322-9.
15. Ghendon Y (1990). WHO strategy for the global elimination of new cases of hepatitis B. Vaccine, 8, 129-33.
16. Gomaa AI, Khan SA, Toledano MB, et al (2008). Hepatocellular carcinoma: Epidemiology, risk factors and pathogenesis. World J Gastroenterol, 14, 4300-8.
17. Hajjarizadeh B (2008). Systematic Review, Meta-analysis and modeling of hepatitis B data in Iran for estimating prevalenc and spacial distribution of hepatitis B using GIS in 2001-2006.[Report in Persian], Salaamat Pajoohan Nikan Institute: Tehran.
18. Hajiani E, Masjedzadeh R, Hasehemi J, et al (2005). Risk factors for hepatocellulr carcinoma in southern Iran. Saudi Med J, 26, 974-7.
19. Kanematsu M, Hoshi H, Imaeda T, et al (1997). Detection and characterization of hepatic tumors: Value of combined helical CT hepatic arteriography and CT during arterial portography. AJR Am J Roentgenol, 168, 1193.
20. Kao, JH and Chen DS (2005). Changing disease burden of hepatocellular carcinoma in the Far East and Southeast Asia. Liver International, 25, 696-703.
21. Khosravi A, Taylor R, Naghavi M, et al (2007). Mortality in the Islamic Republic of Iran, 1964-2004. Bull WHO, 85, 607-14.
22. Koriech O, Al-Kuhaymi R (1994). Profile of cancer in Riyadh armed forces hospital. Ann Saudi Med, 14, 187-94.
23. Kumar V, Fausto N, Abbas A (2003). Robbins & Cotran Pathologic Basis of Disease (7th ed.). Saunders. 914-7.
24. Larcos G, Sorokopud H, Berry G, et al (1998). Sonographic screening for hepatocellular carcinoma in patients with chronic hepatitis or cirrhosis. Am J Roentgenol, 171, 433.
25. Law MG, Roberts SK, Dore GJ, et al (2000). Primary hepatocellular carcinoma in Australia, 1978-1997: Increasing incidence and mortality. Med J Aust, 173, 403-5.
26. Mariotti S, D'Errigo P, Mastroeni S, et al (2003). Years of life lost due to premature mortality in Italy. Eur J Epidemiol, 18, 513-21.
27. Merat S, Malekzadeh R, Rezvan H, et al (2000). Hepatitis B in Iran. Arch Iran Med, 3, 192-201.
28. McGlynn KA, London WT (2005). Epidemiology and natural history of hepatocellular carcinoma. Best Practice & Res Clin Gastroenterol, 19, 3-23.
29. Mousavi SM, Alavian SM, Goya MM, et al (2007). Report of national cancer registration in Iran 2005-2006. Ministry of health and medical education office of health deputy center for disease control and prevention cancer office: Tehran.
30. Nagasue N, Ogawa Y, Yukaya H, et al (1985). Serum levels of estrogens and testosterone in cirrhotic men with and without hepatocellular carcinoma. Gastroenterology, 88, 768-72.
31. Naghavi M (2004). Death report from 23 provinces in Iran. 1st edition. Tehran: Ministry of Health.
32. Pourhoseingholi MA, Faghihzadeh S, Hajizadeh E, et al (2009). Bayesian estimation of colorectal cancer mortality in the presence of misclassification in Iran. Asian Pac J Cancer Prev, 10, 691-4.
33. Pourhoseingholi MA, Faghihzadeh S, Hajizadeh E, et al (2010). Bayesian analysis of gastric cancer mortality in Iranian population. Gastroenterol Hepatol Bed to Bench, 3, 15-8.
34. Parkin DM, Bray F, Ferlay J, et al (2005). Global cancer statistics, 2002. CA Cancer J Clin, 55, 74-108.
35. Shamszad M, Farzadgan H (1982). Hepatitis B related cirrhosis and hepatocellular carcinoma in Iran. J Iranian Med Council, 8, 238.
36. Siddique I, El-Naga HA, Memon A, et al (2004).CLIP score as a prognostic indicator for hepatocellular carcinoma: experience with patients in the Middle East. Euro J Gastro Hepatol, 16, 675-80.
37. Somi MH (2005). Hepatocellular Carcinoma. Hepat Mon, 5, 65-76.
38. Taylor-Robinson SD, Foster GR, Arora S, et al (1997). Increase in primary liver cancer in the UK, 1979-1994. Lancet, 350, 1142-3.
39. Tong MJ (1985). Hepatitis B vaccination of neonates and children. Am J Med, 87, 33-5.
40. Tsukuma H, Hiyama T, Tanaka S, et al (1993). Risk factors for hepatocellular carcinoma among patients with chronic liver disease. N Engl J Med, 328, 1797.
41. Velazquez RF, Rodriguez M, Navascues CA, et al (2003). Prospective analysis of risk factors for hepatocellular carcinoma in patients with liver cirrhosis. Hepatology, 37, 520-7.
42. World Health Organization (2007). Cancer. http://www.who.int/mediacentre/factsheets/fs297/en/